BioNTech (NASDAQ:BNTX) Given “Buy” Rating at Jefferies Financial Group

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Financial Group in a research report issued on Wednesday,MarketScreener reports.

A number of other equities research analysts have also recently commented on BNTX. Cowen reaffirmed a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. UBS Group lifted their price objective on shares of BioNTech from $115.00 to $117.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Morgan Stanley restated an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a report on Monday, November 3rd. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a report on Thursday, October 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $134.10.

BioNTech Price Performance

Shares of BNTX stock opened at $108.48 on Wednesday. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $81.20 and a 12 month high of $129.27. The firm has a market cap of $24.43 billion, a price-to-earnings ratio of -67.46 and a beta of 1.54. The stock has a 50-day moving average price of $102.87 and a 200 day moving average price of $104.91.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same quarter in the prior year, the firm earned $0.81 EPS. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. Research analysts expect that BioNTech will post -3.88 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently bought and sold shares of BNTX. Cerity Partners LLC acquired a new position in BioNTech during the 1st quarter worth approximately $357,000. SBI Securities Co. Ltd. lifted its position in shares of BioNTech by 7.1% in the first quarter. SBI Securities Co. Ltd. now owns 3,673 shares of the company’s stock worth $334,000 after purchasing an additional 244 shares in the last quarter. Whittier Trust Co. lifted its position in shares of BioNTech by 3,846.2% in the first quarter. Whittier Trust Co. now owns 2,052 shares of the company’s stock worth $187,000 after purchasing an additional 2,000 shares in the last quarter. Kestra Private Wealth Services LLC grew its position in BioNTech by 34.2% in the first quarter. Kestra Private Wealth Services LLC now owns 2,659 shares of the company’s stock valued at $242,000 after purchasing an additional 678 shares in the last quarter. Finally, Allianz Asset Management GmbH increased its stake in BioNTech by 44.3% in the 1st quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company’s stock valued at $10,989,000 after buying an additional 37,075 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.